Prestige Consumer Healthcare vs PTC Therapeutics
PTC Therapeutics reported revenue of $1.7 billion in fiscal 2025, 1.6 times Prestige Consumer Healthcare's $1.1 billion in fiscal 2026. Prestige Consumer Healthcare's revenue fell 4.3% in its latest year, and PTC Therapeutics' grew 114.5%. Prestige Consumer Healthcare had an operating margin of 28.4%, against 50.1% at PTC Therapeutics. Free cash flow was $246 million at Prestige Consumer Healthcare and $702 million at PTC Therapeutics. Their fiscal years end in different months (March 31 and December 31), so the periods don't line up exactly.
Side by side
| Prestige Consumer Healthcare | PTC Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2026, Mar 31, 2026 | FY2025, Dec 31, 2025 |
| Revenue | $1.1B | $1.7B |
| Revenue growth | −4.3% | 114.5% |
| Revenue growth a year, last 5 years | 2.9% | 35.4% |
| Gross margin | 54.7% | — |
| Operating margin | 28.4% | 50.1% |
| Net margin | 17.5% | 39.4% |
| Free cash flow | $246M | $702M |
| Free cash flow margin | 22.6% | 40.6% |
| Return on capital | 8.2% | — |
| Net debt to EBITDA | 2.8x | — |
| Dividends and buybacks | $156M | $0M |
| Change in diluted share count | −2.7% | 14.9% |
| Last close | $42.98 | $65.44 |
| P/E at the last close | 13.3× | — |
| Insider trades, last 12 months | sold $424,424 | sold $55.5 million |
| Piotroski F-score | 5 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Prestige Consumer HealthcarePTC Therapeutics
Operating margin
Percent of revenue
Prestige Consumer HealthcarePTC Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Prestige Consumer HealthcarePTC Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Prestige Consumer Healthcare and PTC Therapeutics pages.